Eurizon Capital SGR S.p.A. Sells 27,262 Shares of Quest Diagnostics Incorporated $DGX

Eurizon Capital SGR S.p.A. decreased its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 12.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 195,302 shares of the medical research company’s stock after selling 27,262 shares during the period. Eurizon Capital SGR S.p.A.’s holdings in Quest Diagnostics were worth $45,518,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of DGX. BlackRock Inc. bought a new position in shares of Quest Diagnostics in the 2nd quarter worth $1,965,923,000. EdgePoint Investment Group Inc. increased its holdings in Quest Diagnostics by 35.1% during the 1st quarter. EdgePoint Investment Group Inc. now owns 2,243,869 shares of the medical research company’s stock worth $439,753,000 after purchasing an additional 582,797 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Quest Diagnostics by 0.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,949,535 shares of the medical research company’s stock valued at $382,085,000 after buying an additional 17,987 shares during the last quarter. Bank of America Corp DE bought a new stake in shares of Quest Diagnostics in the second quarter worth $410,151,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Quest Diagnostics by 11.3% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 942,407 shares of the medical research company’s stock worth $199,743,000 after purchasing an additional 95,804 shares during the last quarter. 88.06% of the stock is currently owned by institutional investors and hedge funds.

Quest Diagnostics Stock Performance

Shares of NYSE:DGX opened at $259.46 on Friday. The company’s 50 day simple moving average is $241.23 and its 200 day simple moving average is $215.58. The stock has a market capitalization of $28.55 billion, a price-to-earnings ratio of 25.84, a price-to-earnings-growth ratio of 2.32 and a beta of 0.55. Quest Diagnostics Incorporated has a 1 year low of $171.18 and a 1 year high of $262.00. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.70 and a quick ratio of 1.58.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings results on Thursday, October 22nd. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.87 by $0.13. Quest Diagnostics had a return on equity of 16.21% and a net margin of 9.53%. The company had revenue of $3.10 billion for the quarter, compared to analyst estimates of $3.05 billion. During the same quarter last year, the company posted $2.60 EPS. The company’s revenue for the quarter was up 10.0% compared to the same quarter last year. As a group, research analysts predict that Quest Diagnostics Incorporated will post 11.29 EPS for the current fiscal year.

Quest Diagnostics Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 27th. Shareholders of record on Tuesday, January 12th will be paid a dividend of $0.86 per share. This represents a $3.44 dividend on an annualized basis and a dividend yield of 1.3%. The ex-dividend date of this dividend is Tuesday, January 12th. Quest Diagnostics’s payout ratio is presently 34.26%.

Insider Activity

In other news, Director Gary Pfeiffer sold 1,203 shares of the stock in a transaction on Monday, October 26th. The stock was sold at an average price of $243.00, for a total value of $292,329.00. Following the completion of the transaction, the director directly owned 29,802 shares in the company, valued at approximately $7,241,886. This represents a 3.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Michael Prevoznik sold 22,677 shares of the firm’s stock in a transaction on Friday, August 28th. The shares were sold at an average price of $243.11, for a total value of $5,513,005.47. Following the sale, the senior vice president directly owned 37,557 shares in the company, valued at approximately $9,130,482.27. This trade represents a 37.65% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 67,702 shares of company stock valued at $16,730,269. 0.88% of the stock is currently owned by insiders.

More Quest Diagnostics News

Investors following DGX have been watching these news items:

• Positive Sentiment: A Yahoo Finance article says DGX could be 31% undervalued following a push for the RESULTS Act, providing a potentially supportive policy and valuation angle. Quest Diagnostics stock could be undervalued following RESULTS Act push
• Neutral Sentiment: SVP Patrick Plewman sold 11,717 shares for about $3.02 million, reducing his holdings by 44.38%. The sale was made under a pre-arranged Rule 10b5-1 plan, which makes it a less definitive signal about his view of the company. Quest Diagnostics insider share sale
• Negative Sentiment: Zacks lowered its Q4 2026 EPS estimate to $2.66 from $2.70, partially offsetting the upward revisions for other periods.

Analyst Ratings Changes

DGX has been the subject of a number of analyst reports. JPMorgan Chase & Co. raised their target price on shares of Quest Diagnostics from $220.00 to $250.00 and gave the company a “neutral” rating in a research report on Tuesday, July 28th. Robert W. Baird set a $262.00 price target on Quest Diagnostics in a research report on Friday, October 23rd. Barclays increased their price objective on Quest Diagnostics from $250.00 to $260.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. Truist Financial raised their price objective on Quest Diagnostics from $250.00 to $260.00 and gave the company a “hold” rating in a research report on Monday, September 21st. Finally, Mizuho upped their target price on Quest Diagnostics from $235.00 to $260.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $248.70.

About Quest Diagnostics

Quest Diagnostics (NYSE: DGX) is a provider of diagnostic information services, conducting laboratory tests that help physicians and other health care professionals diagnose, monitor and manage medical conditions. Its services include routine blood and other clinical laboratory testing, anatomic pathology, and specialized molecular and genetic testing. The company serves patients, physicians, hospitals, health plans, employers and government organizations. In addition to testing performed through its laboratories and patient service centers, Quest offers services such as workplace drug testing and diagnostic support for clinical research.